Cefodizime (THR-221) in the field of internal medicine

Yoshio Kobayashi, Hiroshi Kawabe, Yoshiaki Itaya, Ippei Fujimori

研究成果: Article査読

抄録

Eight patients—5 with acute pneumonia. 1 with chronic bronchitis. 1 with infected bronchiectasis and 1 with acute pyelonephritis due to Escherichia coli-were given 2 g of cefodizime (THR-221), a newly developed cephalosporin antibiotic, b.i.d. intravenously for periods ranging from 8.5∼15.5 days. Of the 5 patients with pneumonia, 4 were successfully treated, but 1 needed further treatment with piperacillin. Sputum culture of 1 of the 4 successfully treated patients revealed Streptococcus pneumoniae. No significant side-effects were observed. Transient elevation of S-GOT, S-GPT, Al-P and γ-GTP was observed in one patient.

本文言語English
ページ(範囲)400-404
ページ数5
ジャーナルChemotherapy
36
DOI
出版ステータスPublished - 1988

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

フィンガープリント 「Cefodizime (THR-221) in the field of internal medicine」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル